Janssen Wins EU Fast-Track Status For CAR-T Therapy Cilta-Cel
Filing Of Potential Multiple Myeloma Treatment Planned For H1
Executive Summary
Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.